Sensulin Is Developing a New Type of Freedom from Diabetes

"Glucose-responsive insulin basically is like a chemical pancreas. It sits in the subcutaneous tissue and releases more insulin when you need it and less when you don't. So the the hope would be that from a patient's perspective it's very passive and helps them manage their blood sugar throughout the day without too much effort," says Mike Moradi, CEO & Co-founder of Sensulin. A member of the StartUp Health T1D Moonshot Community, we caught up with Moradi at the recent ADA Scientific Sessions to find out more about his company's innovative treatment for diabetes.
💉 Glucose-Responsive Insulin: Sensulin is developing a glucose-responsive insulin that acts like a chemical pancreas, releasing insulin as needed, simplifying diabetes management for patients.
🧑‍🔬 Expert Team: The team includes former Amylin scientists and executives with significant experience in diabetes treatments, aiming to create a first-in-class product.
🧪 Pre-Clinical Stage: Sensulin is in the pre-clinical stage, finalizing its candidate formulation and preparing for first-in-human trials.
🌐 Innovative Approach: Integrating traditional pharmaceuticals with AI and smart sensors to enhance drug development and patient care.
---
Connect with Health Transformers: www.startuphea...
Become a Health Moonshot Champion: www.startuphea...
Apply to Health Transformer University: www.startuphea...
Connect with StartUpHealth:
Website: www.startuphea...
Instagram: / startuphealth
Twitter: / startuphealth
Podcast: startup-health...